WOW JUST WOW!
Dr. Stanley Hirsch, D.Phil., has been the Group Chief Executive Officer at FuturaGene plc, since August 17, 2007 and also serves as its President. Dr. Hirsch has been Chief Executive Officer of FuturaGene Limited since August 2007. Dr. Hirsch served as the Chief Executive Officer of CBD Technologies Ltd. since 1998. He served as President of CBD Technologies, Ltd. He served as an Executive Director of Foamix Pharmaceuticals Ltd. He joined CBD Technologies in March 1995. Dr. Hirsch has extensive executive and board level experience for more than the past 25 years in private and publicly listed companies in biopharmaceutical and agricultural biotech industries, among others, including direct experience in raising capital and leading M&A activity together with multi-cultural management skills, having managed companies in Israel, Brazil, UK, China and the United States. Prior to CBD, he was responsible for business development for a privately held group of healthcare companies, where he was responsible for structuring and managing joint ventures, startup companies, technology licensing and new product acquisitions. Previously, Dr. Hirsch served as General Manager of two diagnostics development companies, including Portman Pharmaceutical Industries. He has been involved in the development of automated systems for plant tissue culture and is a Co-Inventor of patents in Plant Biotechnology and Micro Propagation Systems. Dr. Hirsch has served as an Advisor to Venture Capital Funds and as a strategy and business development Advisor to various companies in the field of drug development, tissue regeneration and diagnostics. He has filled various board of director, general management and business development positions in the pharmaceutical and genetic diagnostics fields. He has been the Chairman of Foamix Pharmaceuticals Ltd. since May 16, 2016. Dr. Hirsch serves as Chairman of the Board of Directors of the Registrant. He has been Chairman and Director of OWC Pharmaceutical Research Corp. since July 24, 2017. He has been Executive Director of FuturaGene plc., August 17, 2007. He has been a Director of Foamix Pharmaceuticals Ltd. since February 2005. Dr. Hirsch's educational experience includes a D.Phil in Cell Biology and Immunology from Oxford University, UK in 1982, a B.Sc. degree with honors in Medical Biochemistry from the University of Capetown, South Africa in 1979, among other academic honors and awards from Oxford University and University of Capetown.
Collapse Detail
Corporate Headquarters
10 Dominion Street
London, Greater London EC2M 2EE
United Kingdom
Phone: 44 20 8332 6882
Fax: --
Board Members Memberships
2005-Present
Chairman
Foamix Pharmaceuticals Ltd.
2007-Present
Group Chief Executive Officer, President and Executive Director
FuturaGene, LTD.
2017-Present
Chairman
OWC Pharmaceutical Research Corp.
Education
PhD 1982
University of Oxford
BS 1979
University of Cape Town
Other Affiliations
CBD Technologies, Ltd.
University of Oxford
University of Cape Town
Foamix Pharmaceuticals Ltd.
OWC Pharmaceutical Research Corp.
Annual Compensation
There is no Annual Compensation data available.
Stocks Options
There is no Stock Options data available.
Total Compensation
There is no Total Compensation data available.
Request Profile Update
\
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.
Stock Quotes
Market data is delayed at least 15 minutes.
Dr. Stanley Hirsch, D.Phil., has been the Group Chief Executive Officer at FuturaGene plc, since August 17, 2007 and also serves as its President. Dr. Hirsch has been Chief Executive Officer of FuturaGene Limited since August 2007. Dr. Hirsch served as the Chief Executive Officer of CBD Technologies Ltd. since 1998. He served as President of CBD Technologies, Ltd. He served as an Executive Director of Foamix Pharmaceuticals Ltd. He joined CBD Technologies in March 1995. Dr. Hirsch has extensive executive and board level experience for more than the past 25 years in private and publicly listed companies in biopharmaceutical and agricultural biotech industries, among others, including direct experience in raising capital and leading M&A activity together with multi-cultural management skills, having managed companies in Israel, Brazil, UK, China and the United States. Prior to CBD, he was responsible for business development for a privately held group of healthcare companies, where he was responsible for structuring and managing joint ventures, startup companies, technology licensing and new product acquisitions. Previously, Dr. Hirsch served as General Manager of two diagnostics development companies, including Portman Pharmaceutical Industries. He has been involved in the development of automated systems for plant tissue culture and is a Co-Inventor of patents in Plant Biotechnology and Micro Propagation Systems. Dr. Hirsch has served as an Advisor to Venture Capital Funds and as a strategy and business development Advisor to various companies in the field of drug development, tissue regeneration and diagnostics. He has filled various board of director, general management and business development positions in the pharmaceutical and genetic diagnostics fields. He has been the Chairman of Foamix Pharmaceuticals Ltd. since May 16, 2016. Dr. Hirsch serves as Chairman of the Board of Directors of the Registrant. He has been Chairman and Director of OWC Pharmaceutical Research Corp. since July 24, 2017. He has been Executive Director of FuturaGene plc., August 17, 2007. He has been a Director of Foamix Pharmaceuticals Ltd. since February 2005. Dr. Hirsch's educational experience includes a D.Phil in Cell Biology and Immunology from Oxford University, UK in 1982, a B.Sc. degree with honors in Medical Biochemistry from the University of Capetown, South Africa in 1979, among other academic honors and awards from Oxford University and University of Capetown.
Collapse Detail
Corporate Headquarters
10 Dominion Street
London, Greater London EC2M 2EE
United Kingdom
Phone: 44 20 8332 6882
Fax: --
Board Members Memberships
2005-Present
Chairman
Foamix Pharmaceuticals Ltd.
2007-Present
Group Chief Executive Officer, President and Executive Director
FuturaGene, LTD.
2017-Present
Chairman
OWC Pharmaceutical Research Corp.
Education
PhD 1982
University of Oxford
BS 1979
University of Cape Town
Other Affiliations
CBD Technologies, Ltd.
University of Oxford
University of Cape Town
Foamix Pharmaceuticals Ltd.
OWC Pharmaceutical Research Corp.
Annual Compensation
There is no Annual Compensation data available.
Stocks Options
There is no Stock Options data available.
Total Compensation
There is no Total Compensation data available.
Request Profile Update
\
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.
Stock Quotes
Market data is delayed at least 15 minutes.
